Promising topline results for intralymphatic Diamyd® in patients with LADA

/PRNewswire/ -- The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA, in which...

Related Keywords

Norway ,Sweden ,Stockholm ,Uppsala ,Uppsala Lan ,Norwegian ,Karolinska Institutet ,Ingridk Hals ,Ulf Hannelius ,Karolinska University Hospital ,University Hospital In Trondheim ,Company European Phase Iib ,Europen Association For The Study Of Diabetes ,Norwegian University Of Science ,Uppsala University Hospital ,Company Certified Adviser ,Latent Autoimmune Diabetes ,Phd Ingridk Hals ,Europen Association ,Diamyd Medical ,Norwegian University ,Molecular Medicine ,Olavs Hospital ,University Hospital ,Stockholm County ,Karolinska University ,Autoimmune Diabetes ,European Phase ,Uppsala University ,Nextcell Pharma ,Nasdaq First North Growth Market ,Certified Adviser ,Diamyd Medical Ab ,Health Care Amp Hospitals ,Pharmaceuticals ,Medical Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,